Compare VSTS & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | ALVO |
|---|---|---|
| Founded | 1936 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2023 | N/A |
| Metric | VSTS | ALVO |
|---|---|---|
| Price | $9.25 | $3.65 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.88 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 997.5K | 532.2K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,839,000.00 | N/A |
| Revenue This Year | N/A | $12.28 |
| Revenue Next Year | $1.67 | $21.29 |
| P/E Ratio | ★ N/A | $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $3.03 |
| 52 Week High | $9.80 | $11.85 |
| Indicator | VSTS | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 75.88 | 49.60 |
| Support Level | $7.24 | $3.03 |
| Resistance Level | $9.80 | $3.93 |
| Average True Range (ATR) | 0.32 | 0.21 |
| MACD | 0.15 | 0.06 |
| Stochastic Oscillator | 97.47 | 67.46 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.